Hong Kong After the Hong Kong Exchanges and Clearing Limited’s (HKEX) 2018 move to allow pre-revenue biotech companies to raise capital in Hong Kong under its Chapter 18A mechanism, biotech listings surged with pre-clinical companies chosing to list on HKEX as a means of accessing global capital, raising around HKD 118 billion…
Hong Kong Hong Kong Exchanges and Clearing Limited (HKEX) chief executive Nicolas Aguzin has stepped down after a term fraught with upheaval. Having survived COVID-19 isolation, under Aguzin HKEX was confronted with strict regulatory crackdowns and has seen a drop in funds raised from initial public offerings by almost 40 percent. Newly…
Hong Kong Although well-established as Asia’s leading financial services and trading hub, Hong Kong has never truly been globally competitive in the innovation and technology space, despite piecemeal initiatives to bolster its standing in the field. However, with the publication of a comprehensive new Innovation and Technology Development Blueprint, the time might…
Hong Kong While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub for health tech start-ups, just as important are the multinational pharma companies with commercial operations in the city, providing Hong…
Hong Kong Hong Kong provides some of the best and most efficient healthcare in Asia, with Hong Kongers living to over 85 on average (compared to 83 in Singapore and 78 in mainland China), and the World Health Organisation ranks the city among the top 20 healthcare systems globally. However, unlike many…
China A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully integrated internationally competitive bay area to rival that of its US west coast namesake. Staggering Fundamentals Home to 87…
Hong Kong 2018 marked a significant milestone in Hong Kong’s journey towards creating a vibrant biotech market for investors which allows Asian innovation to receive the funding it needs to progress. It was in that year that the Hong Kong Stock Exchange (HKEX) launched the bold and visionary move of allowing clinical-stage…
Hong Kong Insighta, formed this year as a 50/50 joint venture between genomics-focused outfit Prenetics and one of the city’s most feted scientific sons, Professor Dennis Lo, is aiming to change the face of cancer care via widespread early detection. While early detection is widely recognised as crucial to enhancing cancer…
Hong Kong Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research landscape. Strengthened by its experience in conducting COVID-19 vaccine trials, the global trends towards clinical research in Asia and more…
China Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise Chinese investment in its biotech sector more closely. Against this backdrop, and despite many of the leading lights in global…
Hong Kong Albert Wong of the Hong Kong Science and Technology Parks Corporation (HKSTP) outlines how Hong Kong has developed as an innovation hub, building on its established areas of finance and trading. Wong also discusses the importance of life science companies with HKSTP’s portfolio, the challenges of talent attraction, and the…
Hong Kong Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory head, Derek Chang, highlights how early access to innovative therapies in the Hong Kong-Greater Bay Area (GBA) can unlock winning…
See our Cookie Privacy Policy Here